ALK-IN-23
ALK-IN-23 is a potent ALK inhibitor with IC50 values of 1.6 nM, 0.71 nM and 1.3 nM for ALKWT, ALKL1196M and ALKG1202R. ALK-IN-23 can block cell cycle in G2 phase and induce apoptosis. ALK-IN-23 inhibits cancer cell migration and colony formation in vitro. ALK-IN-23 exhibits antitumor activity in H2228 xenograft nude mice model with hypotoxicity.
For research use only. We do not sell to patients.
- CAS No.: 3033549-18-4
- Formula: C26H29ClN8O3S
- Molecular Weight:569.08
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
IC50: 1.6 nM (ALKWT), 0.71 nM (ALKL1196M), 1.3 nM (ALKG1202R)[1]
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A549 | IC50 |
1.33 μM
Compound: Y28
|
Antiproliferative activity against EGFR-positive human A549 cells incubated for 72 hrs and measured by CCK-8 assay
Antiproliferative activity against EGFR-positive human A549 cells incubated for 72 hrs and measured by CCK-8 assay
|
[PMID: 35939995] |
| HCT-116 | IC50 |
1.56 μM
Compound: Y28
|
Antiproliferative activity against human HCT-116 cells incubated for 72 hrs and measured by CCK-8 assay
Antiproliferative activity against human HCT-116 cells incubated for 72 hrs and measured by CCK-8 assay
|
[PMID: 35939995] |
| KARPAS-299 | IC50 |
0.015 μM
Compound: Y28
|
Antiproliferative activity against NPM-ALK-positive human KARPAS-299 cells incubated for 72 hrs and measured by CCK-8 assay
Antiproliferative activity against NPM-ALK-positive human KARPAS-299 cells incubated for 72 hrs and measured by CCK-8 assay
|
[PMID: 35939995] |
| MCF7 | IC50 |
2.22 μM
Compound: Y28
|
Antiproliferative activity against human MCF7 cells incubated for 72 hrs and measured by CCK-8 assay
Antiproliferative activity against human MCF7 cells incubated for 72 hrs and measured by CCK-8 assay
|
[PMID: 35939995] |
| NCI-H1581 | IC50 |
1.87 μM
Compound: Y28
|
Antiproliferative activity against human NCI-H1581 cells incubated for 72 hrs and measured by CCK-8 assay
Antiproliferative activity against human NCI-H1581 cells incubated for 72 hrs and measured by CCK-8 assay
|
[PMID: 35939995] |
| NCI-H2228 | IC50 |
0.017 μM
Compound: Y28
|
Antiproliferative activity against EML4-ALK-positive human NCI-H2228 cells incubated for 72 hrs and measured by CCK-8 assay
Antiproliferative activity against EML4-ALK-positive human NCI-H2228 cells incubated for 72 hrs and measured by CCK-8 assay
|
[PMID: 35939995] |
| NCI-H3122 | IC50 |
0.012 μM
Compound: Y28
|
Antiproliferative activity against EML4-ALK-positive human NCI-H3122 cells incubated for 72 hrs and measured by CCK-8 assay
Antiproliferative activity against EML4-ALK-positive human NCI-H3122 cells incubated for 72 hrs and measured by CCK-8 assay
|
[PMID: 35939995] |
| NCI-H460 | IC50 |
8.21 μM
Compound: Y28
|
Antiproliferative activity against human NCI-H460 cells incubated for 72 hrs and measured by CCK-8 assay
Antiproliferative activity against human NCI-H460 cells incubated for 72 hrs and measured by CCK-8 assay
|
[PMID: 35939995] |
| PC-3 | IC50 |
1.23 μM
Compound: Y28
|
Antiproliferative activity against human PC-3 cells incubated for 72 hrs and measured by CCK-8 assay
Antiproliferative activity against human PC-3 cells incubated for 72 hrs and measured by CCK-8 assay
|
[PMID: 35939995] |
ALK-IN-23 (compound Y28) (0-5 μM; 72h) has highly inhibitory activity against H3122, H2228, Karpas299 and A549[1]. ALK-IN-23 (25-100 nM; 3 days) clearly reduces the number of H2228 cell colonies, and almost completely abolishes the formation of colonies at 100 nM[1]. ALK-IN-23 (100-200 nM; 48 h) facilitates the apoptosis of H2228 cells[1]. ALK-IN-23 (5-10 nM; 24 and 48 h) is effective to block the migration of most cells at a dose of 10 nM[1]. ALK-IN-23 (25-100 nM; overnight) significantly increases the percentage of cells in the G2 phase[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:H3122, H2228, Karpas299 and A549
-
Concentration:0-5 μM
-
Incubation Time:72 h
-
Result:Exhibited highly inhibitory activity against H3122, H2228, Karpas299 and A549 with IC50s of 12 nM, 17 nM, 15 nM and 1.33 μM.
-
Cell Line:H2228 cells
-
Concentration:100 nM, 200 nM
-
Incubation Time:48 h
-
Result:Facilitated the apoptosis of H2228 cells in a dose dependent manner and exhibited a more pro-apoptotic effect than that of Ceritinib (HY-15656).
-
Cell Line:H2228 cells
-
Concentration:5 nM and 10 nM
-
Incubation Time:24 and 48 h
-
Result:Blocked the migration of most cells at a dose of 10 nM (migration rate: 24 h 2.31%, 48 h: 5.01%).
-
Cell Line:H2228 cells
-
Concentration:25 nM, 50 nM, 100 nM
-
Incubation Time:Overnight
-
Result:Significantly increased the percentage of cells in the G2 phase from 11.28% to 73.23% in a dramatic dose-dependent manner, accompanied by a resultant loss of G1-and S-phase populations.
ALK-IN-23 (25 and 50 mg/kg; IG; once every 2 days; for 14 days) exhibited gentle antitumor efficacy and no significant weight loss in H2228 xenograft mice model[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Female BALB/c nude mice (5×106 cells H2228 cells suspended in serum-free media were injected into the flanks)[1]
-
Dosage:25 and 50 mg/kg
-
Administration:IG; once every 2 days; for 14 days
-
Result:Presented moderate antitumor efficacy with the tumor growth inhibition (TGI) of 70.46% at 50 mg/kg.
Possessed gentle antitumor efficacy and exhibited no significant weight loss.
Chemical Information
-
CAS No. 3033549-18-4
-
Molecular Weight 569.08
-
Formula C26H29ClN8O3S
-
SMILES
CC(S(=O)(C1=CC=CC=C1NC2=NC(NC3=CC=C4C(NN=C4NC(CN5CCCC5)=O)=C3)=NC=C2Cl)=O)C
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)